Cargando…
Impact of Intravenous Trehalose Administration in Patients with Niemann–Pick Disease Types A and B
Background and Aims: Niemann–Pick disease (NPD) types A (NPA) and B (NPB) are caused by deficiency of the acid sphingomyelinase enzyme, which is encoded by the SMPD1 gene, resulting in progressive pathogenic accumulation of lipids in tissues. Trehalose has been suggested as an autophagy inducer with...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8745869/ https://www.ncbi.nlm.nih.gov/pubmed/35011993 http://dx.doi.org/10.3390/jcm11010247 |
_version_ | 1784630451038584832 |
---|---|
author | Mobini, Moein Radbakhsh, Shabnam Kubaski, Francyne Eshraghi, Peyman Vakili, Saba Vakili, Rahim Khalili, Manijeh Varesvazirian, Majid Jamialahmadi, Tannaz Alamdaran, Seyed Ali Sayedi, Seyed Javad Rajabi, Omid Emami, Seyed Ahmad Reiner, Željko Sebkar, Amirhossein |
author_facet | Mobini, Moein Radbakhsh, Shabnam Kubaski, Francyne Eshraghi, Peyman Vakili, Saba Vakili, Rahim Khalili, Manijeh Varesvazirian, Majid Jamialahmadi, Tannaz Alamdaran, Seyed Ali Sayedi, Seyed Javad Rajabi, Omid Emami, Seyed Ahmad Reiner, Željko Sebkar, Amirhossein |
author_sort | Mobini, Moein |
collection | PubMed |
description | Background and Aims: Niemann–Pick disease (NPD) types A (NPA) and B (NPB) are caused by deficiency of the acid sphingomyelinase enzyme, which is encoded by the SMPD1 gene, resulting in progressive pathogenic accumulation of lipids in tissues. Trehalose has been suggested as an autophagy inducer with therapeutic neuroprotective effects. We performed a single-arm, open-label pilot study to assess the potential efficacy of trehalose treatment in patients with NPA and NPB patients. Methods: Five patients with NPD type A and B were enrolled in an open-label, single-arm clinical trial. Trehalose was administrated intravenously (IV) (15 g/week) for three months. The efficacy of trehalose in the management of clinical symptoms was evaluated in patients by assessing the quality of life, serum biomarkers, and high-resolution computed tomography (HRCT) of the lungs at the baseline and end of the interventional trial (day 0 and week 12). Results: The mean of TNO-AZL Preschool children Quality of Life (TAPQOL) scores increased in all patients after intervention at W12 compared to the baseline W0, although the difference was not statistically significant. The serum levels of lyso-SM-509 and lyso-SM were decreased in three and four patients out of five, respectively, compared with baseline. Elevated ALT and AST levels were decreased in all patients after 12 weeks of treatment; however, changes were not statistically significant. Pro-oxidant antioxidant balance (PAB) was also decreased and glutathione peroxidase (GPX) activity was increased in serum of patients at the end of the study. Imaging studies of spleen and lung HRCT showed improvement of symptoms in two patients. Conclusions: Positive trends in health-related quality of life (HRQoL), serum biomarkers, and organomegaly were observed after 3 months of treatment with trehalose in patients with NPA and NPB. Although not statistically significant, due to the small number of patients enrolled, these results are encouraging and should be further explored. |
format | Online Article Text |
id | pubmed-8745869 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-87458692022-01-11 Impact of Intravenous Trehalose Administration in Patients with Niemann–Pick Disease Types A and B Mobini, Moein Radbakhsh, Shabnam Kubaski, Francyne Eshraghi, Peyman Vakili, Saba Vakili, Rahim Khalili, Manijeh Varesvazirian, Majid Jamialahmadi, Tannaz Alamdaran, Seyed Ali Sayedi, Seyed Javad Rajabi, Omid Emami, Seyed Ahmad Reiner, Željko Sebkar, Amirhossein J Clin Med Article Background and Aims: Niemann–Pick disease (NPD) types A (NPA) and B (NPB) are caused by deficiency of the acid sphingomyelinase enzyme, which is encoded by the SMPD1 gene, resulting in progressive pathogenic accumulation of lipids in tissues. Trehalose has been suggested as an autophagy inducer with therapeutic neuroprotective effects. We performed a single-arm, open-label pilot study to assess the potential efficacy of trehalose treatment in patients with NPA and NPB patients. Methods: Five patients with NPD type A and B were enrolled in an open-label, single-arm clinical trial. Trehalose was administrated intravenously (IV) (15 g/week) for three months. The efficacy of trehalose in the management of clinical symptoms was evaluated in patients by assessing the quality of life, serum biomarkers, and high-resolution computed tomography (HRCT) of the lungs at the baseline and end of the interventional trial (day 0 and week 12). Results: The mean of TNO-AZL Preschool children Quality of Life (TAPQOL) scores increased in all patients after intervention at W12 compared to the baseline W0, although the difference was not statistically significant. The serum levels of lyso-SM-509 and lyso-SM were decreased in three and four patients out of five, respectively, compared with baseline. Elevated ALT and AST levels were decreased in all patients after 12 weeks of treatment; however, changes were not statistically significant. Pro-oxidant antioxidant balance (PAB) was also decreased and glutathione peroxidase (GPX) activity was increased in serum of patients at the end of the study. Imaging studies of spleen and lung HRCT showed improvement of symptoms in two patients. Conclusions: Positive trends in health-related quality of life (HRQoL), serum biomarkers, and organomegaly were observed after 3 months of treatment with trehalose in patients with NPA and NPB. Although not statistically significant, due to the small number of patients enrolled, these results are encouraging and should be further explored. MDPI 2022-01-04 /pmc/articles/PMC8745869/ /pubmed/35011993 http://dx.doi.org/10.3390/jcm11010247 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Mobini, Moein Radbakhsh, Shabnam Kubaski, Francyne Eshraghi, Peyman Vakili, Saba Vakili, Rahim Khalili, Manijeh Varesvazirian, Majid Jamialahmadi, Tannaz Alamdaran, Seyed Ali Sayedi, Seyed Javad Rajabi, Omid Emami, Seyed Ahmad Reiner, Željko Sebkar, Amirhossein Impact of Intravenous Trehalose Administration in Patients with Niemann–Pick Disease Types A and B |
title | Impact of Intravenous Trehalose Administration in Patients with Niemann–Pick Disease Types A and B |
title_full | Impact of Intravenous Trehalose Administration in Patients with Niemann–Pick Disease Types A and B |
title_fullStr | Impact of Intravenous Trehalose Administration in Patients with Niemann–Pick Disease Types A and B |
title_full_unstemmed | Impact of Intravenous Trehalose Administration in Patients with Niemann–Pick Disease Types A and B |
title_short | Impact of Intravenous Trehalose Administration in Patients with Niemann–Pick Disease Types A and B |
title_sort | impact of intravenous trehalose administration in patients with niemann–pick disease types a and b |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8745869/ https://www.ncbi.nlm.nih.gov/pubmed/35011993 http://dx.doi.org/10.3390/jcm11010247 |
work_keys_str_mv | AT mobinimoein impactofintravenoustrehaloseadministrationinpatientswithniemannpickdiseasetypesaandb AT radbakhshshabnam impactofintravenoustrehaloseadministrationinpatientswithniemannpickdiseasetypesaandb AT kubaskifrancyne impactofintravenoustrehaloseadministrationinpatientswithniemannpickdiseasetypesaandb AT eshraghipeyman impactofintravenoustrehaloseadministrationinpatientswithniemannpickdiseasetypesaandb AT vakilisaba impactofintravenoustrehaloseadministrationinpatientswithniemannpickdiseasetypesaandb AT vakilirahim impactofintravenoustrehaloseadministrationinpatientswithniemannpickdiseasetypesaandb AT khalilimanijeh impactofintravenoustrehaloseadministrationinpatientswithniemannpickdiseasetypesaandb AT varesvazirianmajid impactofintravenoustrehaloseadministrationinpatientswithniemannpickdiseasetypesaandb AT jamialahmaditannaz impactofintravenoustrehaloseadministrationinpatientswithniemannpickdiseasetypesaandb AT alamdaranseyedali impactofintravenoustrehaloseadministrationinpatientswithniemannpickdiseasetypesaandb AT sayediseyedjavad impactofintravenoustrehaloseadministrationinpatientswithniemannpickdiseasetypesaandb AT rajabiomid impactofintravenoustrehaloseadministrationinpatientswithniemannpickdiseasetypesaandb AT emamiseyedahmad impactofintravenoustrehaloseadministrationinpatientswithniemannpickdiseasetypesaandb AT reinerzeljko impactofintravenoustrehaloseadministrationinpatientswithniemannpickdiseasetypesaandb AT sebkaramirhossein impactofintravenoustrehaloseadministrationinpatientswithniemannpickdiseasetypesaandb |